Foghorn Therapeutics Inc. — Q1 2022 Form 10-Q
Business context and period. Clinical-stage biotechnology company developing medicines that target the chromatin regulatory system. This unaudited report covers the three months ended March 31, 2022, compared with Q1 2021. Foghorn had no approved products and generated no product-sales revenue. Its lead programs, FHD-286 and FHD-609, were in Phase 1 studies.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 or comparison |
|---|---|---|
| Collaboration revenue | $3.9 million | $0.3 million |
| Research and development expense | $24.5 million | $18.7 million |
| General and administrative expense | $7.2 million | $4.7 million |
| Total operating expenses | $31.7 million | $23.4 million |
| Operating loss | $27.8 million | $23.1 million |
| Net loss | $26.9 million | $23.0 million |
| Net loss per share | $0.65 | $0.62 |
| Operating cash flow | $271.5 million provided | $23.1 million used |
- Liquidity: At March 31, cash and cash equivalents were $213.6 million and marketable securities were $211.1 million, totaling $424.7 million. Restricted cash of $1.7 million is additional.
- Cash flow context: Q1 operating cash flow included collection of the $300.0 million Lilly collaboration receivable; it does not reflect recurring operating cash generation. Investing activities used $159.4 million, mainly for purchases of marketable securities.
- Balance sheet: Total liabilities were $415.9 million and stockholders’ equity was $72.4 million. Liabilities included $347.1 million of deferred revenue and $56.6 million of operating lease liabilities. The filing says the Oxford debt was paid off in December 2021; Q1 2022 interest expense was zero.
- Margins: Product gross margin is not applicable because the company had no product sales. Revenue was collaboration-based; the filing does not present a product margin measure.
Material changes versus Q1 2021
- Revenue increased by $3.6 million, primarily from $3.8 million recognized under the Lilly collaboration, partly offset by lower Merck collaboration revenue.
- R&D expense rose $5.8 million, reflecting higher FHD-286 and FHD-609 program costs, platform research, and personnel costs as clinical programs and headcount expanded.
- G&A expense rose $2.5 million, primarily due to higher personnel, stock-based compensation, and public-company professional costs.
- Net loss increased by $3.9 million. The absence of Oxford debt interest expense and higher interest income partly offset higher operating expenses.
- Cash, cash equivalents, and marketable securities increased substantially following Lilly payments and investment of funds; Q1 cash flow comparisons are heavily affected by the one-time $300.0 million collection.
Outlook, management commentary, and risks
- Management expected cash, cash equivalents, and marketable securities to fund operating expenses and capital needs for at least 12 months from the financial statement issuance date. The company expects continued operating losses and significant expense increases as it advances programs and platform research.
- The Lilly arrangement covers six programs directed at five targets. Lilly paid a $300.0 million upfront amount, and separately bought 4.0 million shares for $80.0 million. The combined arrangement included $337.8 million allocated to deferred revenue; $333.3 million remained at March 31, 2022 and was expected to be recognized through 2029 as work is performed. Recognition depends on cost-to-cost estimates and may vary by period.
- Potential collaboration milestones were excluded from the transaction price because they were constrained by uncertainty. Future milestone, royalty, and collaboration economics are not assured. Lilly has specified termination rights and target-substitution rights; Foghorn’s development and commercialization participation may depend on program opt-in or opt-out choices.
- Foghorn also remains eligible for potential Merck milestones and royalties, but timing and receipt are uncertain. $13.8 million of Merck deferred revenue remained at quarter-end, expected to be recognized through 2028.
- Key risks include clinical and regulatory uncertainty, the ability to raise additional capital, reliance on collaborators and external research/manufacturing organizations, and the estimates underlying collaboration revenue recognition. The company reported no material litigation and no material changes to the risk factors in its 2021 Form 10-K. COVID-19 had not significantly affected operations to date, but future effects remained uncertain.
Important facts for investors to verify
- Whether available liquidity and any future financing will support planned clinical and research spending beyond management’s stated 12-month runway.
- Clinical progress, enrollment, safety findings, and timing for FHD-286 and FHD-609; the filing provides no clinical outcome data in this text.
- Whether Lilly and Merck programs progress toward milestones, and how collaboration choices, costs, substitutions, or termination rights may affect economics.
- Changes in cost estimates and the resulting timing or amount of deferred-revenue recognition, particularly for the Lilly agreement.
- Continued growth in R&D spending, stock-based compensation, and share dilution; common shares outstanding were 41.43 million at March 31, 2022.